Cantor Fitzgerald Forecasts Exagen FY2026 Earnings

Exagen Inc. (NASDAQ:XGN - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Exagen in a research report issued on Wednesday, June 11th. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings of ($0.31) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $7.00 target price on the stock. The consensus estimate for Exagen's current full-year earnings is ($0.88) per share.

Exagen (NASDAQ:XGN - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, meeting the consensus estimate of ($0.20). The company had revenue of $15.50 million during the quarter, compared to analyst estimates of $14.55 million. Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. During the same quarter in the previous year, the business posted ($0.19) EPS.

XGN has been the subject of several other research reports. William Blair reiterated an "outperform" rating on shares of Exagen in a research note on Wednesday, March 12th. UBS Group reiterated an "overweight" rating on shares of Exagen in a research note on Thursday, May 15th. Canaccord Genuity Group lifted their price objective on shares of Exagen from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Tuesday, May 13th. Finally, BTIG Research reiterated a "buy" rating on shares of Exagen in a research note on Wednesday, May 7th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Exagen currently has a consensus rating of "Buy" and an average target price of $7.50.

Exagen Trading Up 4.5%

Shares of NASDAQ:XGN traded up $0.32 during mid-day trading on Friday, hitting $7.44. The company had a trading volume of 263,253 shares, compared to its average volume of 124,680. The firm has a fifty day moving average price of $6.07 and a 200 day moving average price of $4.77. The company has a market capitalization of $158.47 million, a PE ratio of -7.91 and a beta of 1.60. The company has a debt-to-equity ratio of 1.54, a current ratio of 4.05 and a quick ratio of 4.05. Exagen has a one year low of $1.71 and a one year high of $7.75.

Institutional Trading of Exagen

A number of hedge funds and other institutional investors have recently bought and sold shares of XGN. Toronto Dominion Bank bought a new stake in shares of Exagen in the 4th quarter worth $3,655,000. Driehaus Capital Management LLC bought a new stake in shares of Exagen in the 4th quarter worth $1,716,000. Kennedy Capital Management LLC grew its stake in shares of Exagen by 8.8% in the 4th quarter. Kennedy Capital Management LLC now owns 184,473 shares of the company's stock worth $756,000 after acquiring an additional 14,920 shares in the last quarter. Palumbo Wealth Management LLC grew its stake in shares of Exagen by 14.4% in the 1st quarter. Palumbo Wealth Management LLC now owns 99,205 shares of the company's stock worth $356,000 after acquiring an additional 12,501 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Exagen by 11.9% in the 4th quarter. Geode Capital Management LLC now owns 98,057 shares of the company's stock worth $402,000 after acquiring an additional 10,442 shares in the last quarter. Institutional investors own 75.25% of the company's stock.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).